emd 53998 has been researched along with spironolactone in 1 studies
| Studies (emd 53998) | Trials (emd 53998) | Recent Studies (post-2010) (emd 53998) | Studies (spironolactone) | Trials (spironolactone) | Recent Studies (post-2010) (spironolactone) |
|---|---|---|---|---|---|
| 112 | 0 | 9 | 7,222 | 960 | 1,923 |
| Protein | Taxonomy | emd 53998 (IC50) | spironolactone (IC50) |
|---|---|---|---|
| Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
| Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
| Estrogen receptor | Homo sapiens (human) | 5.702 | |
| Glucocorticoid receptor | Homo sapiens (human) | 4.0745 | |
| Progesterone receptor | Homo sapiens (human) | 1.675 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 0.0315 | |
| Androgen receptor | Homo sapiens (human) | 0.3585 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.406 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 1.9025 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 6.92 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, L; Dallemagne, C; Endre, Z; Margolin, S; Miric, G; Taylor, SM | 1 |
1 other study(ies) available for emd 53998 and spironolactone
| Article | Year |
|---|---|
Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Blood Glucose; Body Weight; Calcium Chloride; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drinking; Eating; Fibrosis; Glomerular Filtration Rate; Heart Ventricles; In Vitro Techniques; Kidney; Male; Mineralocorticoid Receptor Antagonists; Myocardial Contraction; Myocardium; Norepinephrine; Pyridones; Quinolines; Rats; Rats, Wistar; Spironolactone; Thiadiazines; Vasoconstriction; Vasoconstrictor Agents | 2001 |